Methods
Laboratoriumsmedizin
Humangenetik
- Myeloid, atypical chronic myelogenic leukemia, chronic neutrophilic leukemia, NGS panel
- AML / Myeloid, acute myeloid leukemia - prognostic panel 1, NGS
- AML / Myeloid, acute myeloid leukemia - panel 2 other therapeutic options, NGA panel
- AML / Myeloid, acute myeloid leukemia - panel 3 sensitive for sAML and prognostic, NGS panel
- Lymphoid, chronic lymphocytic leukemia, prognostic NGS panel
- BCR-ABL t(9;22)
- CBFB-MYH11 inv(16)
- CBFB-MYH11 inv(16) fusion type A
- CCAAT / enhancer-binding protein, alpha (CEBPA)
- Chronic neutrophilia caused by heterozygous mutation in the CSF3R gene
- Chronic lymphoblastic leukemia (B cell): prognostic markers IGHV, TP53, SF3B1, NOTCH1
- Myeloid, chronic myelomonocytic leukemia: core panel diagnostic and prognostic, NGS
- FIP1L1/PDGFRA fusion gene (microdeletion 4q12)
- FLT3 gene: FMS-related tyrosine kinase 3, qualitative
- KIT mutations verification in the case of AML
- Immunoglobulin heavy chains variable gene cluster, IGHV
- Clonality verification T-cell receptor, beta and gamma chain (TCRB, TCRG)
- Large granular lymphocytic leukemia, T-LGL and NK-LGL: STAT3 mutations
- Lymphoid, unclear disease entity - NGS panel
- Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, AHN panel, NGS
- Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, prognostic panel small, NGS panel
- Myeloid, myelodysplastic syndrome with isolated del(5q), markers with therapeutic relevance, NGS panel
- Myeloid, myelodysplastic/myeloproliferative neoplasms, MDS / MPN overlap, NGS panel
- Myeloid, myelodysplastic syndrome MDS diagnostic, NGS panel
- Myeloid, myelodysplastic syndrome MDS - prognostic markers, NGS panel
- Myeloid, myelodysplastic syndrome MDS, markers with therapeutic relevance, NGS panel
- MLL / MLL-PTD (partial Tandem duplication)
- MLL-MLLT2 (AF4) Transcripts(4;11)(q21;q23) in the case of ALL
- MPL mutations in the case of thrombocytopenia or myelofibrosis
- Myeloid, myeloproliferative neoplasia, NGS panel 1
- Myeloid, myeloproliferative neoplasia, extended diagnosis panel, NGS panel 2
- Myeloid, myeloproliferative neoplasia, extended prognostic panel, NGS
- Multiplex aberration screening, 28 markers (for AML, ALL, CML)
- Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel according to MIPSS70 or MIPSS70 plus, NGS panel
- Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel MIPSS70 or MIPSS70 plus extended, NGS panel
- Myeloid, unclear disease entity, NGS panel
- Myeloid neoplasias (AML, CMML, MDS, MPN) - mutation screening
- PML/RAR alpha t(15;17)
- PML/RAR alpha t(15;17) quantitative, L type (BCR1), S type (BCR3) and V type (BCR2)
- AA / myeloid, Aplastic Anemia - prognostic and therapeutic markers, NGS panel
- Myeloid, myeloproliferative neoplasia, polycythemia vera - prognostic panel, NGS
- Polycythemia vera (PV)
- RUNX1 mutation verification
- RUNX1-RUNX1T1 t(8;21) / AML1-ETO t(8;21)
- RUNX1-RUNX1T1 t(8;21)(q22;q22), quantitative / AML1-ETO
Mikrobiologie
Contact
Laboratoriumsmedizin Dortmund
44137 Dortmund
Materialannahme
Mo - Fr: 7.30 -17.00 Uhr
GFLiD Dispatch material and distribution
- +49 2306 94096-80
- +49 2306 94096-83
- http://www.gflid.de/
GFLiD Dispatch material, distribution, transport
Andreas Orwat
- +49 2306 94096-60
- +49 2306 94096-63
- http://www.gflid.de/